Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G, Conteduca V, Brighi N, Scarpi E, Basso U, Fornarini G, Mosca A, Nicodemo M, Banna GL, Lolli C, Schepisi G, Ravaglia G, Bondi I, Ulivi P, De Giorgi U. Gurioli G, et al. Among authors: ravaglia g. BMC Med. 2022 Jan 31;20(1):48. doi: 10.1186/s12916-022-02244-0. BMC Med. 2022. PMID: 35101049 Free PMC article.
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Schepisi G, Casadei C, Toma I, Poti G, Iaia ML, Farolfi A, Conteduca V, Lolli C, Ravaglia G, Brighi N, Altavilla A, Martinelli G, De Giorgi U. Schepisi G, et al. Among authors: ravaglia g. Cancers (Basel). 2021 Feb 17;13(4):840. doi: 10.3390/cancers13040840. Cancers (Basel). 2021. PMID: 33671294 Free PMC article. Review.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U. Altavilla A, et al. Among authors: ravaglia g. Expert Opin Pharmacother. 2020 Dec;21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12. Expert Opin Pharmacother. 2020. PMID: 32783772 Review.
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.
Conteduca V, Scarpi E, Matteucci F, Caroli P, Ravaglia G, Fantini L, Gurioli G, Schepisi G, Wetterskog D, Menna C, Burgio SL, Lolli C, Paganelli G, Attard G, De Giorgi U. Conteduca V, et al. Among authors: ravaglia g. JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00302. JCO Precis Oncol. 2019. PMID: 35100689
Plasma Androgen Receptor in Prostate Cancer.
Conteduca V, Gurioli G, Brighi N, Lolli C, Schepisi G, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M, Romeo A, De Giorgi U. Conteduca V, et al. Among authors: ravaglia g. Cancers (Basel). 2019 Nov 4;11(11):1719. doi: 10.3390/cancers11111719. Cancers (Basel). 2019. PMID: 31689899 Free PMC article. Review.
125 results